A quick peek into the report
Table of Contents
Product Definition
2.1 Scope of Study
2.2 Inclusion and Exclusion Criteria of the Report
2.2.1 Inclusion Criteria
2.2.2 Exclusion Criteria of the Report
2.3 Key Questions Answered in the Report
3.1 Primary Data Sources
3.2 Secondary Data Sources
3.3 Data Sources Categorization
3.4 Selection Criteria for Company Profiles
3.5 Assumptions and Limitations
4.1 Key Developments and Strategies
4.1.1 Regulatory and Legal Landscape
4.1.2 Funding Activities and Investments
4.1.3 Partnerships, Collaborations, Alliances, and Business Expansions
4.1.4 New Offerings
4.1.5 Mergers and Acquisition Activities
4.2 Market Share Analysis
4.2.1 Market Share Analysis (by Company)
4.2.2 Market Share Analysis for Global Spinal Cord Stimulation Devices Market, 2019
4.2.3 Market Share Analysis for Global Deep Brain Stimulation Devices Market, 2019
4.2.4 Market Share Analysis for Global Auditory Brainstem Implant Market, 2019
4.3 Product Analysis
4.4 Growth Share Analysis
5.1 Impact on Global Treatment Landscape
5.2 Impact on Adoption Rate of Neurostimulation Devices
5.3 Impact on Global Market Size
5.4 Entry Barriers and Opportunities for the Companies in Global Neurostimulation Devices Market
6.1 Regulatory Framework
6.1.1 Regulations in North America
6.1.1.1 U.S.
6.1.1.2 Canada
6.1.2 Regulations in Europe
6.1.3 Regulations in Asia-Pacific
6.1.3.1 National Medical Products Administration (NMPA)
6.1.3.2 Pharmaceutical and Medical Device Agency (PMDA)
6.1.3.3 Therapeutic Goods Administration (TGA)
6.2 Societies, Consortium, and Associations for Global Neurostimulation Devices Market
6.3 Patent Analysis
6.4 Product Pipeline
7.1 Market Overview
7.2 Evolution of the Neurostimulation Therapy
7.3 Global Market Scenario
7.4 Assumptions and Limitations
7.5 Market Dynamics
7.6 Impact Analysis
7.6.1 Market Drivers
7.6.1.1 Growing Incidence of Neurological Disorders
7.6.1.2 Increased Side-Effects of Pain Management Medications in Geriatric Population
7.6.1.3 Limited Success Rate of Drugs Targeting Specific Disease
7.6.1.4 Advent of Sedentary Lifestyles Resulting in Massive Burden of Chronic Pain
7.6.1.5 Growing Concerns Pertaining to Pelvic Health of Geriatric Population
7.6.2 Market Restraints
7.6.2.1 Financial Burden of Product Recalls
7.6.2.2 Increased Regulatory Scrutiny
7.6.2.3 High Cost of Equipment
7.6.3 Market Opportunities
7.6.3.1 Evolution of Biomarker-Based Therapeutics Enabling Early Diagnostics of Neurological Disorders
7.6.3.2 Development of Closed Loop Neuromodulation
8.1 Implantable Neurostimulation Devices
8.1.1 Spinal Cord Stimulation Devices
8.1.1.1 Rechargeable Spinal Cord Stimulation
8.1.1.2 Non-Rechargeable Spinal Cord Stimulation
8.1.2 Auditory Brainstem Implant
8.1.3 Deep Brain Stimulation (DBS)
8.1.3.1 Single Channel DBS
8.1.3.2 Dual Channel DBS
8.1.4 Vagus Nerve Stimulation (VNS) Devices
8.1.5 Sacral Nerve Stimulation (SNS) Devices
8.1.6 Hypoglossal Nerve Stimulation Devices
8.1.7 Others Implantable Neurostimulation Devices
8.2 Non-Implantable Neurostimulation Devices
8.2.1 Transcranial Magnetic Stimulation (TMS)
8.2.2 Others Non-Implantable Neurostimulation Device
9.1 Pain Management
9.2 Hearing Loss
9.3 Parkinson’s Disease
9.4 Epilepsy
9.5 Urinary and Fecal Incontinence
9.6 Depression
9.7 Other Applications
10.1 North America
10.1.1 North America Neurostimulation Devices Market (by Product Type)
10.1.1.1 North America Implantable Neurostimulation Devices Market (by Type)
10.1.2 North America Neurostimulation Devices Market (by Country)
10.1.2.1 U.S.
10.1.2.2 Canada
10.2 Europe
10.2.1 Europe Neurostimulation Devices Market (by Product Type)
10.2.1.1 Europe Implantable Neurostimulation Devices Market (by Type)
10.2.2 Europe Neurostimulation Devices Market (by Country)
10.2.2.1 Germany
10.2.2.2 U.K.
10.2.2.3 France
10.2.2.4 Italy
10.2.2.5 Spain
10.2.2.6 Russia
10.2.2.7 Switzerland
10.2.2.8 Rest-of-Europe
10.3 Asia-Pacific
10.3.1 Asia-Pacific Neurostimulation Devices Market (by Product Type)
10.3.1.1 Asia-Pacific Implantable Neurostimulation Devices Market (by Type)
10.3.2 Asia-Pacific Neurostimulation Devices Market (by Country)
10.3.2.1 Japan
10.3.2.2 China
10.3.2.3 India
10.3.2.4 Australia
10.3.2.5 South Korea
10.3.2.6 Rest-of-Asia-Pacific
10.4 Latin America
10.4.1 Latin America Neurostimulation Devices Market (by Product Type)
10.4.1.1 Latin America Implantable Neurostimulation Devices Market (by Type)
10.4.2 Latin America Neurostimulation Devices Market (by Country)
10.4.2.1 Brazil
10.4.2.2 Mexico
10.4.2.3 Argentina
10.4.2.4 Rest-of-Latin America
10.4.3 Middle East and Africa (MEA)
10.4.4 Middle East and Africa Neurostimulation Devices Market (by Product Type)
10.4.5 Middle East and Africa Implantable Neurostimulation Devices Market (by Type)
11.1 Abbott Laboratories
11.1.1 Company Overview
11.1.2 Role of Abbott Laboratories in the Neurostimulation Device Market
11.1.3 Financials
11.1.4 SWOT Analysis
11.2 Axonics Modulation Technologies, Inc.
11.2.1 Company Overview
11.2.2 Role of Axonics Modulation Technologies, Inc. in the Neurostimulation Devices Market
11.2.3 Financials
11.2.4 SWOT Analysis
11.3 Beijing PINS Medical Co., Ltd.
11.3.1 Company Overview
11.3.2 Role of Beijing PINS Medical Co., Ltd. in the Neurostimulation Devices Market
11.3.3 SWOT Analysis
11.4 Boston Scientific Corporation
11.4.1 Company Overview
11.4.2 Role of Boston Scientific Corporation in the Neurostimulation Devices Market
11.4.3 Financials
11.4.4 SWOT Analysis
11.5 Cochlear Ltd.
11.5.1 Company Overview
11.5.2 Role of Cochlear Ltd. in the Neurostimulation Devices Market
11.5.3 Financials
11.5.4 SWOT Analysis
11.6 electroCore, Inc.
11.6.1 Company Overview
11.6.2 Role of electroCore, Inc. in the Neurostimulation Devices Market
11.6.3 Financials
11.6.4 SWOT Analysis
11.7 Helius Medical Technologies, Inc.
11.7.1 Company Overview
11.7.2 Helius Medical Technologies, Inc. in the Neurostimulation Devices Market
11.7.3 Financials
11.7.4 SWOT Analysis
11.8 Inspire Medical Systems, Inc.
11.8.1 Company Overview
11.8.2 Role of Inspire Medical System, Inc. in the Neurostimulation Devices Market
11.8.3 Financials
11.8.4 SWOT Analysis
11.9 Laborie Medical Technologies, Inc.
11.9.1 Company Overview
11.9.2 Role of Laborie Medical Technologies, Inc. in the Neurostimulation Devices Market
11.9.3 SWOT Analysis
11.10 LivaNova PLC
11.10.1 Company Overview
11.10.2 Role of LivaNova PLC in the Neurostimulation Devices Market
11.10.3 Financials
11.10.4 SWOT Analysis
11.11 MED-EL
11.11.1 Company Overview
11.11.2 Role of MED-EL in the Neurostimulation Devices Market
11.11.3 SWOT Analysis
11.12 Medtronic Plc
11.12.1 Company Overview
11.12.2 Role of Medtronic plc in the Neurostimulation Devices Market
11.12.3 Financials
11.12.4 SWOT Analysis
11.13 NeuroMetrix, Inc.
11.13.1 Company Overview
11.13.2 Role of NeuroMetrix, Inc. in the Neurostimulation Devices Market
11.13.3 Financials
11.13.4 SWOT Analysis
11.14 NeuroPace, Inc.
11.14.1 Company Overview
11.14.2 Role of NeuroPace, Inc. in the Neurostimulation Devices Market
11.14.3 SWOT Analysis
11.15 Nevro Corporation
11.15.1 Company Overview
11.15.2 Role of Nevro Corporation in the Neurostimulation Devices Market
11.15.3 Financials
11.15.4 SWOT Analysis
11.16 Sonova
11.16.1 Company Overview
11.16.2 Role of Sonova in the Neurostimulation Devices Market
11.16.3 Financials
11.16.4 SWOT Analysis
11.17 Synapse Biomedical Inc.
11.17.1 Company Overview
11.17.2 Role of Synapse Biomedical Inc. in the Neurostimulation Devices Market
11.17.3 SWOT Analysis
11.18 The Magstim Company Limited
11.18.1 Company Overview
11.18.2 Role of The Magstim Company Limited in the Neurostimulation Devices Market
11.18.3 SWOT Analysis
Table 1: Mortality Due to Opioid-Use Disorders
Table 4.1: Product Analysis of Neurostimulation Devices
Table 5.1: Impact of COVID-19 on Treatment Landscape
Table 6.1: Global Neurostimulation Devices Market (Association/Consortium/Society)
Table 6.2: Product Pipeline Analysis of Neurostimulation Devices
Table 7.1: Some of the Recalled Neurostimulation Devices
Table 8.1: Specification of Different Spinal Cord Stimulation Device Offered by Different Companies
Table 10.1: Prevalence of Neurological Diseases in North America, 2014-2017
Table 10.2: Prevalence of Neurological Diseases in the U.S., 2014-2017
Table 10.3: Prevalence of Neurological Diseases in Canada, 2014-2017
Table 10.4: Prevalence of Neurological Diseases in Europe, 2014-2017
Table 10.5: Prevalence of Neurological Diseases in Germany, 2014-2017
Table 10.6: Prevalence of Neurological Diseases in the U.K., 2014-2017
Table 10.7: Prevalence of Neurological Diseases in France, 2014-2017
Table 10.8: Prevalence of Neurological Diseases in Italy, 2014-2017
Table 10.9: Prevalence of Neurological Diseases in Spain, 2014-2017
Table 10.10: Prevalence of Neurological Diseases in Russia, 2014-2017
Table 10.11: Prevalence of Neurological Diseases in Switzerland, 2014-2017
Table 10.12: Prevalence of Neurological Diseases in Asia-Pacific, 2014-2017
Table 10.13: Prevalence of Neurological Diseases in Japan, 2014-2017
Table 10.14: Prevalence of Neurological Diseases in China, 2014-2017
Table 10.15: Prevalence of Neurological Diseases in India, 2014-2017
Table 10.16: Prevalence of Neurological Diseases in Australia, 2014-2017
Table 10.17: Prevalence of Neurological Diseases in South Korea, 2014-2017
Table 10.18: Prevalence of Neurological Diseases in Latin America, 2014-2017
Table 10.19: Prevalence of Neurological Diseases in Brazil, 2014-2017
Table 10.20: Prevalence of Neurological Diseases in Mexico, 2014-2017
Table 10.21: Prevalence of Neurological Diseases in Argentina, 2014-2017
Figure 1: Percentage Share of Neurological Disorders Causing Global Deaths (2005, 2015, and 2030)
Figure 2: Global Neurostimulation Devices Market, 2019-2030
Figure 3: Growth Promoting and Growth Inhibiting Factors of Global Neurostimulation Devices Market
Figure 4: Global Neurostimulation Devices Market: Patent Analysis (by Year of Filing), January 2016-May 2020
Figure 5: Share of Key Developments and Strategies, January 2016-May 2020
Figure 6: Market Share Analysis for the Global Neurostimulation Devices Market (by Company), 2019
Figure 7: Global Neurostimulation Devices Market (by Product Type), 2019-2030
Figure 8: Global Neurostimulation Devices Market (by Application), 2019 and 2030
Figure 9: Global Neurostimulation Devices Market (by Region), 2019 and 2030
Figure 2.1: Global Neurostimulation Devices Market Segmentation
Figure 3.1: Global Neurostimulation Devices Market Research Methodology
Figure 3.2: Primary Research
Figure 3.3: Secondary Research
Figure 3.4: Shares of Key Company Profiles
Figure 3.5: Assumptions and Limitations
Figure 4.1: Share of Key Developments and Strategies (January 2016-May 2020)
Figure 4.2: Regulatory and Legal (by Company), January 2016-May 2020
Figure 4.3: Funding Activities and Investments (by Company), January 2016-May 2020
Figure 4.4: Partnerships, Alliances, Collaboration, and Business Expansions (by Company), January 2016-May 2020
Figure 4.5: New Offerings (by Company), January 2016-May 2020
Figure 4.6: Merger and Acquisition Activities (by Company), January 2016-May 2020
Figure 4.7: Market Share Analysis for the Global Neurostimulation Devices Market, (by Company), 2019
Figure 4.8: Market Share Analysis (by Company) for Global Spinal Cord Stimulation Devices Market, 2019
Figure 4.9: Market Share Analysis (by Company) for Global Deep Brain Stimulation Devices Market, 2019
Figure 4.10: Market Share Analysis (by Company) for Global Auditory Brainstem Implant Market, 2019
Figure 4.11: Growth Share Matrix for Global Neurostimulation Devices Market (by Product), 2019
Figure 5.1: COVID-19 Impact on the Global Elective Surgeries
Figure 5.2: Growth Trend of the Neurostimulation Devices
Figure 5.3: Global Neurostimulation Devices Market: Challenges and Opportunities
Figure 6.1: Global Neurostimulation Devices Market: Patent Analysis (by Year of Filing), January 2016-May 2020
Figure 7.1: Evolution of Neurostimulation Technologies
Figure 7.2: Global Neurostimulation Devices Market, 2019-2030
Figure 7.3: Market Dynamics
Figure 7.4: Impact Analysis of Market Drivers and Challenges
Figure 7.5: Number and Percentage of DALYs for Different Neurological Disorders, 2015
Figure 7.6: Number and Percentage of DALYs for Different Neurological Disorders, 2030
Figure 8.1: Segmentation of Global Neurostimulation Devices Market (by Product Type)
Figure 8.2: Global Neurostimulation Devices Market (by Product Type), 2019-2030
Figure 8.3: Segmentation of Implantable Neurostimulation Devices Market
Figure 8.4: Global Implantable Neurostimulation Devices Market, 2019-2030
Figure 8.5: Global Implantable Neurostimulation Devices Market, (by Product Type), 2019-2030
Figure 8.6: Mechanism Action of Spinal Cord Stimulation Device
Figure 8.7: Global Spinal Cord Stimulation Devices Market, (2019-2030)
Figure 8.8: Global Rechargeable Spinal Cord Stimulation (SCS) Devices Market, (2020-2030)
Figure 8.9: Global Non-Rechargeable Spinal Cord Stimulation Devices Market, (2019-2030)
Figure 8.10: Mechanism of Action of Auditory Brainstem Implants
Figure 8.11: Global Auditory Brainstem Implant Market, (2019-2030)
Figure 8.12: Global Deep Brain Stimulation Devices Market, (2019-2030)
Figure 8.13: Global Single-Channel Deep Brain Stimulation Devices Market, (2019-2030)
Figure 8.14: Global Dual-Channel Deep Brain Stimulation Devices Market, (2019-2030)
Figure 8.15: Global Vagus Nerve Stimulation Devices Market, (2019-2030)
Figure 8.16: Global Sacral Nerve Stimulation Devices Market, (2019-2030)
Figure 8.17: Global Hypoglossal Nerve Stimulation Devices Market, (2019-2030)
Figure 8.18: Others Implantable Neurostimulation Devices Market, (2019-2030)
Figure 8.19: Segmentation of Non-Implantable Neurostimulation Devices Market
Figure 8.20: Global Non-Implantable Neurostimulation Devices Market, (by Product Type), 2019-2030
Figure 8.21: Global Transcranial Magnetic Stimulation (TMS) Devices Market, (2019-2030)
Figure 8.22: Others Non-Implantable Neurostimulation Devices Market, (2019-2030)
Figure 9.1: Segmentation of Neurostimulation Devices Market (by Application)
Figure 9.2: Global Neurostimulation Devices Market (by Application), 2019-2030
Figure 9.3: Global Neurostimulation Devices Market (Pain Management), 2019-2030
Figure 9.4: Global Neurostimulation Devices Market (Hearing Loss), 2019-2030
Figure 9.5: Global Neurostimulation Devices Market (Parkinson’s Disease), 2019-2030
Figure 9.6: Global Neurostimulation Devices Market (Epilepsy), 2019-2030
Figure 9.7: Global Neurostimulation Devices Market (Urinary and Fecal Incontinence), 2019-2030
Figure 9.8: Global Neurostimulation Devices Market (Depression), 2019-2030
Figure 9.9: Global Neurostimulation Devices Market (Other Applications), 2019-2030
Figure 10.1: Global Neurostimulation Devices Market (by Region), 2019 and 2030
Figure 10.2: North America Neurostimulation Devices Market, 2019-2030
Figure 10.3: North America Neurostimulation Devices Market: Market Dynamics
Figure 10.4: North America Neurostimulation Devices Market (by Product Type), 2019-2030
Figure 10.5: North America Implantable Neurostimulation Devices Market (by Type), 2019-2030
Figure 10.6: North America Neurostimulation Devices Market (by Country), 2019 and 2030
Figure 10.7: Alzheimer’s Dementia in Different Age Groups in the U.S., 2019
Figure 10.8: U.S. Neurostimulation Devices Market, 2019-2030
Figure 10.9: Canada Neurostimulation Devices Market, 2019-2030
Figure 10.10: Europe Neurostimulation Devices Market, 2019-2030
Figure 10.11: Europe Neurostimulation Devices Market: Market Dynamics
Figure 10.12: Europe Neurostimulation Devices Market (by Product Type), 2019-2030
Figure 10.13: Europe Implantable Neurostimulation Devices Market (by Type), 2019-2030
Figure 10.14: Europe Neurostimulation Devices Market (by Country), 2019 and 2030
Figure 10.15: Germany Neurostimulation Devices Market, 2019-2030
Figure 10.16: U.K. Neurostimulation Devices Market, 2019-2030
Figure 10.17: France Neurostimulation Devices Market, 2019-2030
Figure 10.18: Italy Neurostimulation Devices Market, 2019-2030
Figure 10.19: Spain Neurostimulation Devices Market, 2019-2030
Figure 10.20: Russia Neurostimulation Devices Market, 2019-2030
Figure 10.21: Switzerland Neurostimulation Devices Market, 2019-2030
Figure 10.22: Rest-of-Europe Neurostimulation Devices Market, 2019-2030
Figure 10.23: Asia-Pacific Neurostimulation Devices Market, 2019-2030
Figure 10.24: Asia-Pacific Neurostimulation Devices Market: Market Dynamics
Figure 10.25: Asia-Pacific Neurostimulation Devices Market (by Product Type), 2019-2030
Figure 10.26: Asia-Pacific Implantable Neurostimulation Devices Market (by Type), 2019-2030
Figure 10.27: Asia-Pacific Neurostimulation Devices Market (by Country), 2019 and 2030
Figure 10.28: Japan Neurostimulation Devices Market, 2019-2030
Figure 10.29: China Neurostimulation Devices Market, 2019-2030
Figure 10.30: India Neurostimulation Devices Market, 2019-2030
Figure 10.31: Australia Neurostimulation Devices Market, 2019-2030
Figure 10.32: South Korea Neurostimulation Devices Market, 2019-2030
Figure 10.33: Rest-of-Asia-Pacific Neurostimulation Devices Market, 2019-2030
Figure 10.34: Latin America Neurostimulation Devices Market, 2019-2030
Figure 10.35: Latin-America Neurostimulation Devices Market: Market Dynamics
Figure 10.36: Latin America Neurostimulation Devices Market (by Product Type), 2019-2030
Figure 10.37: Latin America Implantable Neurostimulation Devices Market (by Type), 2019-2030
Figure 10.38: Latin America Neurostimulation Devices Market (by Country), 2019 and 2030
Figure 10.39: Brazil Neurostimulation Devices Market, 2019-2030
Figure 10.40: Mexico Neurostimulation Devices Market, 2019-2030
Figure 10.41: Argentina Neurostimulation Devices Market, 2019-2030
Figure 10.42: Rest-of-Latin America Neurostimulation Devices Market, 2019-2030
Figure 10.43: Middle East and Africa Neurostimulation Devices Market, 2019-2030
Figure 10.44: Middle East and Africa Neurostimulation Devices Market: Market Dynamics
Figure 10.45: Middle East and Africa Neurostimulation Devices Market (by Product Type), 2019-2030
Figure 10.46: Middle East and Africa Implantable Neurostimulation Devices Market (by Type), 2019-2030
Figure 11.1: Abbott Laboratories: Overall Product Portfolio
Figure 11.2: Abbott Laboratories: Overall Financials, 2017-2019
Figure 11.3: Abbott Laboratories: Revenue (by Product/Service), 2017-2019
Figure 11.4: Abbott Laboratories: Revenue (by Region), 2017-2019
Figure 11.5: Abbott Laboratories: R&D Expenditure, 2017-2019
Figure 11.6: Abbott Laboratories: SWOT Analysis
Figure 11.7: Axonics Modulation Technologies, Inc.: Overall Product Portfolio
Figure 11.8: Axonics Modulation Technologies, Inc.: Overall Financials, 2017-2019
Figure 11.9: Axonics Modulation Technologies, Inc.: R&D Expenditure, 2017-2019
Figure 11.10: Axonics Modulation Technologies, Inc.: SWOT Analysis
Figure 11.11: Beijing PINS Medical Co., Ltd.: Overall Product Portfolio
Figure 11.12: Beijing PINS Medical Co., Ltd.: SWOT Analysis
Figure 11.13: Boston Scientific Corporation: Overall Product Portfolio
Figure 11.14: Boston Scientific Corporation: Overall Financials, 2017-2019
Figure 11.15: Boston Scientific Corporation: Revenue (by Segment), 2017-2019
Figure 11.16: Boston Scientific Corporation: Revenue (by Sub-segment), 2017-2019
Figure 11.17: Boston Scientific Corporation: Revenue (by Region), 2017-2019
Figure 11.18: Boston Scientific Corporation: R&D Expenditure, 2017-2019
Figure 11.19: Boston Scientific Corporation: SWOT Analysis
Figure 11.20: Cochlear Ltd.: Overall Product Portfolio for Neurostimulation Devices Market
Figure 11.21: Cochlear Ltd.: Overall Financials, 2017-2019
Figure 11.22: Cochlear Ltd.: Revenue (by Segment), 2017-2019
Figure 11.23: Cochlear Ltd.: Revenue (by Region), 2017-2019
Figure 11.24: Cochlear Ltd.: R&D Expenditure
Figure 11.25: Cochlear Ltd.: SWOT Analysis
Figure 11.26: electroCore, Inc.: Overall Product Portfolio
Figure 11.27: electroCore, Inc.: Overall Financials, 2017-2019
Figure 11.28: electroCore, Inc.: Revenue (by Region), 2017-2019
Figure 11.29: electroCore, Inc.: R&D Expenditure, 2017-2019
Figure 11.30: electroCore, Inc.: SWOT Analysis
Figure 11.31: Helius Medical Technologies, Inc.: Overall Product Portfolio
Figure 11.32: Helius Medical Technologies, Inc.: Overall Financials, 2017-2019
Figure 11.33: Helius Medical Technologies, Inc.: R&D Expenditure, 2017-2019
Figure 11.34: Helius Medical Technologies, Inc.: SWOT Analysis
Figure 11.35: Inspire Medical System, Inc.: Overall Product Portfolio
Figure 11.36: Inspire Medical System, Inc.: Overall Financials, 2017-2019
Figure 11.37: Inspire Medical System, Inc.: Revenue (by Region), 2017-2019
Figure 11.38: Inspire Medical System, Inc.: R&D Expenditure, 2017-2019
Figure 11.39: Inspire Medical System Inc.: SWOT Analysis
Figure 11.40: Laborie Medical Technologies, Inc.: Overall Product Portfolio
Figure 11.41: Laborie Medical Technologies, Inc.: SWOT Analysis
Figure 11.42: LivaNova PLC: Overall Product Portfolio
Figure 11.43: LivaNova PLC: Overall Financials, 2017-2019
Figure 11.44: LivaNova PLC (by Segment), 2017-2019
Figure 11.45: LivaNova PLC: Revenue (by Region), 2017-2019
Figure 11.46: LivaNova PLC: R&D Expenditure, 2017-2019
Figure 11.47: LivaNova PLC: SWOT Analysis
Figure 11.48: MED-EL: Overall Product Portfolio
Figure 11.49: MED-EL: SWOT Analysis
Figure 11.50: Medtronic plc: Overall Product Portfolio
Figure 11.51: Medtronic Plc: Overall Financials, 2017-2019
Figure 11.52: Medtronic Plc: Revenue (by Segment), 2017-2019
Figure 11.53: Medtronic Plc: Revenue (by Region), 2017-2019
Figure 11.54: Medtronic Plc: Research and Development Expense, 2017-2019
Figure 11.55: Medtronic plc: SWOT Analysis
Figure 11.56: NeuroMetrix, Inc.: Overall Product Portfolio
Figure 11.57: NeuroMetrix, Inc.: Overall Financials, 2017-2019
Figure 11.58: NeuroMetrix, Inc.: R&D Expenditure, 2017-2019
Figure 11.59: NeuroMetrix, Inc.: SWOT Analysis
Figure 11.60: NeuroPace, Inc.: Overall Product Portfolio
Figure 11.61: NeuroPace, Inc.: SWOT Analysis
Figure 11.62: Nevro Corporation: Overall Product Portfolio
Figure 11.63: Nevro Corporation: Overall Financials, 2017-2019
Figure 11.64: Nevro Corporation: Revenue (by Region), 2017-2019
Figure 11.65: Nevro Corporation: R&D Expenditure, 2017-2019
Figure 11.66: Nevro Corporation: SWOT Analysis
Figure 11.67: Sonova: Overall Product Portfolio
Figure 11.68: Sonova: Overall Financials, 2017-2019
Figure 11.69: Sonova: Revenue (by Segment), 2017-2019
Figure 11.70: Sonova: Revenue (by Region), 2017-2019
Figure 11.71: Sonova: R&D Expenditure, 2017-2019
Figure 11.72: Sonova: SWOT Analysis
Figure 11.73: Synapse Biomedical Inc.: Overall Product Portfolio
Figure 11.74: Synapse Biomedical Inc.: SWOT Analysis
Figure 11.75: The Magstim Company Limited: Overall Product Portfolio
Figure 11.76: The Magstim Company Limited: SWOT Analysis
Report Description
Market Report Coverage - Neurostimulation Devices |
|||
Base Year |
2019 |
Market Size in 2019 |
$7,246.9 Million |
Forecast Period |
2021-2030 |
Value Projection and Estimation by 2030 |
$18,033.0 Million |
CAGR During Forecast Period |
8.87% |
Number of Tables |
28 |
Number of Pages |
266 |
Number of Figures |
189 |
Research Hours |
700 |
|
|
Market Segmentation |
• By Product Type: Implantable and non-implantable Implantable neurostimulation devices can be further segmented into seven types - spinal cord stimulation, auditory brainstem implant, deep brain stimulation, vagus nerve stimulation, sacral nerve stimulation, hypoglossal nerve stimulation, and others. Non-implantable neurostimulation devices can be further segmented into two types - transcranial magnetic stimulation, and others • By Application: Pain management, hearing loss, Parkinson’s disease, epilepsy, urinary and fecal Incontinence, depression, and others |
||
Regional Segmentation |
• North America –U.S. and Canada • Europe – Germany, U.K., France, Italy, Spain, Russia, Switzerland, Rest-of-the-Europe • Asia-Pacific – Japan, China, India, Australia, South Korea, Rest-of-the-Asia-Pacific • Latin America- Brazil, Mexico, Argentina, and Rest-of-the-Latin America • Middle East and Africa |
||
Growth Drivers |
• Growing incidence of neurological disorders • Increased side-effects of pain management medications in geriatric population • Limited success rate of drugs targeting specific diseases • Advent of sedentary lifestyles resulting massive burden of chronic pain • Growing concerns pertaining to pelvic health of geriatric population |
||
Market Challenges |
• Financial burden of product recalls • Increased regulatory scrutiny • High cost of equipment |
||
Market Opportunities |
• Evolution of biomarker-based therapeutics enabling early diagnostics of neurological disorders • Development of closed loop neuromodulation |
||
Key Neurostimulation Devices Companies Profiled |
Abbott Laboratories, Axonics Modulation Technologies, Inc., Beijing PINS Medical Co., Ltd., Boston Scientific Corporation, Cochlear Ltd., electroCore, Inc., Helius Medical Technologies, Inc., Inspire Medical Systems, Inc., Laborie Medical Technologies, Inc., LivaNova PLC, MED-EL, Medtronic plc, NeuroMetrix, Inc., NeuroPace, Inc., Nevro Corporation, Sonova, Synapse BioMedical, Inc., and The Magstim Company Limited |
Key Questions Answered in this Report:
• What is a neurostimulation device? How have different neurostimulation devices evolved over the years?
• What are the advantages of non-invasive and minimally invasive neurostimulation devices?
• What are the major market drivers, challenges, and opportunities in the global neurostimulation devices market?
• What is the global neurostimulation devices market size in terms of revenue in 2020? What is the market size expected to be in 2030?
• How is each segment of the global neurostimulation devices market expected to grow during the forecast period between 2021 to 2030, and what is the revenue expected to be generated by each of the segments by the end of 2030?
• What are the developmental strategies implemented by the key players to sustain in the competitive market?
• What is the growth potential of the neurostimulation devices market in each region, namely, North America, Europe, Asia-Pacific, and the Rest-of-the-World?
• Which type of neurostimulation devices are expected to dominate the market in 2030, and why?
• Which key players of the neurostimulation devices market are expected to grow during the forecast period?
• Which neurostimulation technology is leading the market in 2019 and expected to dominate the market in 2030, and why?
• Which applications are leading the neurostimulation devices market in 2019 and are expected to dominate the market in 2030, and why?
• Which region dominated the global neurostimulation devices market in 2019 and what are the expected trends from each of the regions in the forecast period 2021-2030?
• What is the impact of COVID-19 on the neurostimulation devices market?
• What type of products coming in the upcoming years pertaining to neurostimulation devices?
Market Overview
Neurostimulation devices consider the implantable and non-implantable neurostimulation devices which act on the spinal cord and brain to deliver the electrical stimulation to a targeted area. These types of devices are mainly used in the treatment and management of Parkinson’s disease, bowel and bladder dysfunction, Alzheimer’s disease, and relieving chronic pain of the body. For carrying out innovative research in the field of neurostimulation devices, companies in the market received funding and investments by a few government organizations. The global neurostimulation devices market witnessed approximately 22 funding and investments in the past four years (January 2016-May 2020). For instance, NeuroPace, Inc. received $74 million funding from KCK Group and OrbiMed Advisors for ramping the production of NeuroPace RNS System, which was approved by the FDA in 2013. This device is used for the treatment and management of epileptic seizures.
The companies received a large number of product approvals by the regulatory bodies, including FDA, PMDA, Japan’s Ministry of Health, Labour and Welfare, CE mark certification, European Medical Device Regulation (MDR) certification, and TGA approvals. Medtronic plc, Helius Medical Technologies, BrainsWay, Nevro Corporation, and Cochlear Ltd. received the maximum number of product approvals. For instance, in January 2020, Medtronic plc received CE mark approval for the Percept PC neurostimulator DBS system with BrainSense Technology. This device is used for the treatment of Parkinson’s disease. Moreover., in March 2020, Helius Medical Technologies received approval from Health Canada to commercialize the PoNS Device. This device is used for the treatment and management of multiple sclerosis (MS).
The market is favored by multiple factors, which include rising prevalence of neurological diseases, such as Parkinson’s disease, Alzheimer’s disease, epilepsy, and neuropathic pain. Neurostimulation devices have shown promising results to cure disorders that affect the activity of the nervous system that includes the brain and spinal cord. Furthermore, there are plenty of options available in the neurostimulation devices market offering preventive treatment against such conditions. Such products are therefore being adopted even by professionals and by people of different age groups. Hence, the results of the prevention and treatment of different neurological disorders are accelerating the growth of the neurostimulation devices market.
Elderly population is mostly under pain management treatment for different neurological disorders, which include Parkinson’s disease and Alzheimer’s disease. As in the geriatric population, they are likely to have an increased risk of adverse reactions from pharmacological methods which are used for pain management medications. Thus, such methods that are used for the treatment of neurostimulation disorders consist of minimally invasive methods used for the management of persistent pain and cause no side effects and risk. Addressing chronic diseases that have a high incidence in the geriatric population is expected to gain momentum due to this growing number and shall continue to drive the global neurostimulation devices market.
All these factors are thus, expected to contribute to market growth during the forecast period.
Within the research report, the market is segmented based on product type, application, and region, which highlight value propositions and business models useful for industry leaders and stakeholders. The research also comprises country-level analysis, go-to-market strategies of leading players, future opportunities, among others, to provide a 360-coverage of the domain.
Competitive Landscape
Major players, including Medtronic plc, Boston Scientific Corporation, Cochlear, Ltd., and Abbott Laboratories, among others, led the number of synergistic developments (partnerships and alliances) witnessed by the market. Based on the region, North America is expected to retain a leading position in the market throughout the forecast period 2021-2030, followed by Europe. North America’s market dominance, as well as the market growth in the region, can primarily be attributed to the presence of several established leading players including Abbott Laboratories, Boston Scientific Corporation, Inspire Medical Systems, Inc., Nuvectra Corporation, NeuroMetrix, Inc., among others that make the region one of the attractive markets for neurostimulation devices. These players have entered into strategic partnerships with the leading research centers and universities, and government medical research centers in the region to facilitate the development of their products. For instance, in May 2019, Abbott Laboratories partnered with NIH on the BRAIN (Brain Research through Advancing Innovative Neurotechnologies) initiative to accelerate advancements in neurological science. Likewise, in January 2018, Helius Medical Technologies, Inc. partnered with Key Tronic corporation to provided contract manufacturing for portable neuromodulation stimulator (PoNS) devices.
Global Neurostimulation Devices Market
Analysis and Forecast, 2021-2030